Arcagy/ Gineco Group

This study is testing whether adding a new drug called relatlimab to an existing immunotherapy (nivolumab) works better than nivolumab alone for women with locally advanced cervical cancer. All 77 participants will receive these drugs for 6 weeks before starting their standard ch…

This large, late-stage trial is testing whether adding the immunotherapy drug dostarlimab to standard chemotherapy works better than chemotherapy alone for women with advanced or recurrent endometrial cancer that has a specific genetic marker (MMR deficient). The main goal is to …